Sarepta Therapeutics
SRPT
332 hedge funds and large institutions have $5.5B invested in Sarepta Therapeutics in 2022 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 97 increasing their positions, 129 reducing their positions, and 36 closing their positions.
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
59% more call options, than puts
Call options by funds: $122M | Put options by funds: $76.8M
22% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 36
1% more funds holding
Funds holding: 329 → 332 (+3)
0.03% more ownership
Funds ownership: 83.82% → 83.85% (+0.03%)
4% less capital invested
Capital invested by funds: $5.71B → $5.5B (-$207M)
25% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 129
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$58.7M |
| 2 |
Goldman Sachs
New York
|
+$35.8M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$34.9M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$29.4M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$26.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$78.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$75.2M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$27.5M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$23.1M |
| 5 |
VCP
Varenne Capital Partners
Paris,
France
|
-$23.1M |
SRPT Hedge Fund Activity: Q2 2022 in Review
332 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2022, worth a combined $5.5B — down 3.6% from $5.71B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new SRPT positions and 36 closed out — a net gain of 8 holders — while 97 added to existing stakes and 129 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $58.7M. The largest seller was Sands Capital Management, cutting an estimated $78.9M.
- 332 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2022, up from 329 in Q1 2022.
- Funds reported $5.5B of Sarepta Therapeutics stock for Q2 2022, down 3.6% quarter-over-quarter.
- 44 funds opened new Sarepta Therapeutics positions in Q2 2022 and 36 closed out, a net change of +8 holders.
- The largest Sarepta Therapeutics buyer in Q2 2022 was EcoR1 Capital, an estimated $58.7M added.
- The largest Sarepta Therapeutics seller in Q2 2022 was Sands Capital Management, an estimated $78.9M sold.
Based on aggregated 13F filings for Q2 2022.